Stimcell Energetics, Inc. (STME)
Oxford Ledge is still expanding full research coverage of STME. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Stimcell Energetics develops microcurrent electrical therapy devices for managing diabetes, pain, and related health conditions.
Source: 10-K (2026-05-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-04-10
- 8-K Entry into material agreement; 3.02; Regulation FD disclosure; Financial statements and exhibits 2026-03-20
- 10-Q Quarterly financial report (unaudited) 2026-01-15
- 8-K Regulation FD disclosure; Financial statements and exhibits 2025-12-02
- 10-Q Quarterly financial report (unaudited) 2025-10-14
Source: SEC EDGAR.
Annual results
5 years of annual figures for STME, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2026 | — | -$895,375 | — |
| 2025 | — | -$566,293 | — |
| 2024 | $0 | -$142,486 | — |
| 2023 | $2,762 | -$495,042 | — |
| 2022 | — | -$697,379 | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for STME. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open STME in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.